Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5 AND SODIUM CHLORIDE 0 45 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5 AND SODIUM CHLORIDE 0 45 IN PLASTIC CONTAINER.
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER vs POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate provides magnesium ions, which are essential for various physiological processes. It acts as a cofactor for enzymatic reactions, stabilizes excitable membranes, and antagonizes calcium entry at the neuromuscular junction, leading to reduced acetylcholine release and muscle relaxation. In the CNS, it may act as a noncompetitive antagonist of NMDA receptors, exerting anticonvulsant effects.
Potassium is the major intracellular cation; it is essential for maintenance of membrane potential, nerve impulse transmission, cardiac contractility, and skeletal muscle function. Dextrose provides calories and may decrease protein catabolism. Sodium chloride helps maintain extracellular fluid volume and electrolyte balance.
1 to 4 g intravenously as a 5% to 20% solution, rate not exceeding 150 mg/min; dosing frequency depends on indication (e.g., preeclampsia/eclampsia: 4-5 g IV loading then 1-2 g/hr infusion; hypomagnesemia: 1-2 g IV over 1-2 hours, may repeat based on serum magnesium levels).
Intravenous infusion; dose determined by serum potassium levels and patient condition; typical maintenance: 10-20 mEq potassium per hour; maximum infusion rate: 20 mEq/hour (not to exceed 1 mEq/kg/hour); concentration not to exceed 80 mEq/L via peripheral line. Each 1 L of this product contains 5 mEq potassium chloride, 50 g dextrose, and 77 mEq sodium chloride.
None Documented
None Documented
Terminal half-life approximately 4-5 hours in normal renal function; prolonged in renal impairment (up to 40 hours).
Not applicable for endogenous potassium; infused potassium distributes with a rapid initial phase (~1 h) and a slower terminal phase (~8-12 h) reflecting cellular equilibration
Primarily renal (90-100% as unchanged magnesium). Less than 1% biliary/fecal.
Renal: >90% as potassium ion; minor fecal loss <10%
Category C
Category A/B
Electrolyte
Electrolyte